PCVX

About PCVX

Vaxcyte Inc. is a clinical-stage vaccine company. The Company develops conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its synthetic techniques include advanced chemistry and the XpressCF cell-free protein synthesis platform, licensed from Sutro Biopharma, Inc., or Sutro Biopharma. Its pipeline includes Pneumococcal conjugate vaccine (PCV), VAX-A1, VAX-PG and VAX-GI. Its lead vaccine candidate, VAX-24, is a 24-valent investigational PCV being developed for the prevention of invasive pneumococcal disease (IPD). Its second PCV candidate, VAX-31, is designed to prevent IPD. population. VAX- 24 is intended to improve upon the standard-of-care PCV vaccines for both children and adults. VAX-A1 is a conjugate vaccine candidate designed to prevent disease caused by Group A Streptococcus or Group A Strep. VAX-PG is a protein vaccine candidate targeting the keystone pathogen responsible for periodontitis. VAX-GI is a vaccine program designed to prevent Shigella.